A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism (Q60327368)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

title

A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Jeffrey A Bluestone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Eleonora Trotta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Anthony Coyle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Marc Potempa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Paul H Bessette

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Stephanie L Silveria

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Lauren K Ely

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

K Christopher Garcia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Natasha K Crellin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Isaac J Rondon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

language of work or name

English

0 references

publication date

25 June 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

1005-1014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

2 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

The role of interleukin-2 during homeostasis and activation of the immune system

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

The IL-2/IL-2 receptor system: a current overview

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Binding of small molecules to an adaptive protein-protein interface

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

The structure of interleukin-2 complexed with its alpha receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

IL-2: the first effective immunotherapy for human cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Cytokine dysregulation as a mechanism of graft versus host disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Interleukin-2 and regulatory T cells in graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Interleukin-2: Biology, Design and Application

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Fc-fusion Proteins in Therapy: An Updated View.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Expansion of human regulatory T-cells from patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

"Do you catch my drift?"

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

The role of the NKG2D immunoreceptor in immune cell activation and natural killing

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Vital involvement of a natural killer cell activation receptor in resistance to viral infection.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Specific and nonspecific NK cell activation during virus infection

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Phasercrystallographic software

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Coot: model-building tools for molecular graphics

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

The Phenix software for automated determination of macromolecular structures

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Inference of macromolecular assemblies from crystalline state

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0070-2

7 January 2021

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29942088

12 December 2020

inferred from PubMed ID database lookup

Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29942088

12 December 2020

inferred from PubMed ID database lookup

Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29942088

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/S41591-018-0070-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

PubMed publication ID

29942088

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29942088%20AND%20SRC:MED&resulttype=core&format=json